Search

Displaying results 2521 - 2530 of 9333 in total
  1. Drug

    Amisulpride

    go.drugbank.com/drugs/DB06288
    ApprovedInvestigational

    In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of … [L32759] It is marketed under the brand name Barhemsys.

  2. Drug

    Medium-chain triglycerides

    go.drugbank.com/drugs/DB13959
    ApprovedInvestigational

    In the body, MCTs are broken down into glycerol and free fatty acids, which are directly absorbed into the blood stream and transported to the target organs to exert a range of biological and metabolic … Medium-chain triglycerides (MCTs) are triglycerides made up of a glycerol backbone and three fatty acids with an aliphatic tail of six to 12 carbon atoms.

    Mixtures: LIPOFUNDIN MCT/LCT %10 VIT E INFUZYON ICIN YAG EMULSUYONU, 100 ML, LIPOFUNDIN MCT/LCT %10 VIT E INFUZYON ICIN YAG EMULSUYONU, 250 ML
  3. Drug

    Patiromer

    go.drugbank.com/drugs/DB09263
    ApprovedInvestigational

    Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. … Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015.

  4. Drug

    N-(2-Aminoethyl)-1-aziridineethanamine

    go.drugbank.com/drugs/DB15643
    Experimental

    First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease

    Categories: Agents Acting on the Renin-Angiotensin System
  5. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. … It was rejected for approval for use in the United States.

  6. Drug

    Bithionol

    go.drugbank.com/drugs/DB04813
    ApprovedWithdrawn

    Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. … Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).

  7. Drug

    Mometasone furoate

    go.drugbank.com/drugs/DB14512
    ApprovedInvestigationalVet approved

    Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label][F4292,F4295].

    Products: FUROATO DE MOMETASONA0.1 % LOCION, FUROATO DE MOMETASONA SPRAY NASAL
  8. Drug

    Ethylenediamine

    go.drugbank.com/drugs/DB14189
    Approved

    Sensitivity to ethylenediamine may be identified with a clinical patch test. … Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products.

  9. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    Human serum albumin is the primary protein present in human blood plasma. The main function of albumin is to maintain the oncotic pressure of blood [A33706]. … It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates).

  10. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … late-phase CINV during the first 120 hours post-chemotherapy.